AGÕæÈ˹ٷ½

Predictive Oncology applies AI and a proprietary biobank of 150,000+ tumor samples to support oncology drug discovery and now operates as a single segment focused on AI-driven cancer-therapy development after reclassifying its Birmingham and Eagan businesses to discontinued operations.

The company reported total assets of $3.44M and total liabilities of $5.09M as of June 30, 2025, producing a stockholders' deficit of $(1.65M). Cash and cash equivalents were $506,078. For the six months ended June 30, 2025 the company recorded revenue of $112,992, a net loss of $4.51M (continuing operations loss of $4.26M), and net cash used in continuing operating activities of $4.28M. The company sold its Eagan assets for $625,000 (plus assumed liabilities) and closed related discontinued operations.

Management discloses substantial doubt about the company’s ability to continue as a going concern without additional financing. Nasdaq notified the company of noncompliance but a Hearings Panel granted an extension through December 8, 2025. Subsequent events include a standby equity purchase agreement providing the right to sell up to $10.0M of common stock subject to conditions and a proposed 1-for-15 reverse stock split subject to stockholder approval.

Predictive Oncology (POAI) has scheduled a 2025 Special Meeting to vote on three board-backed items:

• Reverse Stock Split 1-for-15 â€� designed to lift the share price above Nasdaq’s US$1.00 minimum and remedy bid-price and equity deficiencies. Nasdaq has granted an extension until 8 Dec 2025.
• Nasdaq Proposal â€� authorize issuance of up to US$10 million in common stock under a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. Yorkville can purchase shares over 36 months at VWAP minus 4 %, potentially exceeding the 19.99 % “Exchange Cap.â€�
• Adjournment Proposal â€� permits the meeting to be postponed to secure sufficient votes.

The reverse split will consolidate every 15 shares into one, reduce the shares outstanding accordingly and round up fractional entitlements. While the move should improve marketability and preserve the Nasdaq listing, it increases the pool of authorized but unissued shares, raising dilution and anti-takeover concerns. The SEPA offers flexible working-capital financing, yet further share sales will dilute existing holders and depend on shareholder approval to lift the cap.

Failure to pass Proposals 1 or 2 risks delisting and limits access to the full SEPA facility. The board unanimously recommends voting FOR all three proposals.